# Reverse Triple Negative Immune Resistant Breast Cancer

Source: https://onco.cc/trials/nct05076682/  
OnCo record `nct05076682` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab rezetecan, SHR-A2102, Adebrelimab and Mecapegfilgrastim in Triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

Reverse Triple Negative Immune Resistant Breast Cancer is a phase 2 interventional study registered as NCT05076682 by Fudan University, with 80 participants planned, started 2022-06-30 and due to reach its primary completion in 2026-12-31. Interventions recorded: Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz, SHR-A1811, SHR-A2102, SHR-1316, Mecapegfilgrastim, AK131, Theophylline. Conditions recorded: Triple-negative Breast Cancer.

Linked to the drug Mecapegfilgrastim because the registry names it among its interventions and Triple-negative breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05076682
- Phase: 2
- Setting: Reverse Triple Negative Immune Resistant Breast Cancer
- Sponsor: Fudan University
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT05076682: https://clinicaltrials.gov/study/NCT05076682

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Mecapegfilgrastim](https://onco.cc/drugs/mecapegfilgrastim/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)

---
JSON: https://onco.cc/api/v1/entities/nct05076682.json